A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype
Provide written informed consent for the study.
Male or female, age ≥ 18 years and ≤80 years.
ECOG PS 0,1 or 2.
Participants with histologically proven peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH), including: a. angioimmunoblastic T-cell lymphoma, b. follicular helper T-cell lymphoma, follicular type, c. follicular helper T-cell lymphoma, NOS.
Presence of CNS involvement.
Received prior therapies targeting lymphoma.
Participants planned for autologous or allogeneic transplant as consolidation after CR.
Participants with any other malignancy in past 5 years, except for local tumors that have been cured.